44 results about "Cardiac infarction" patented technology

Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.

Compounds of the formulawherein R1, R2, R3, R4, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.

This invention relates to ilexin, drug combination of ilexin and its extraction method, which is used to treat CHD, angina pectoris, stroke, cardiac infarction and other cerebral vascular diseases. It uses ethanol for extraction, adds water into the extract, centrifuges to get the sediments and supernatant. Sediments are added 50-95% ethanol for extraction and filtration, the liquid is concentrated, placed and filtrated, and the sediments are dried to get a part of total saponin, the saponin is crystallized by ethanol to get a part of ilexin. The supernatant is enriched and centrifuged for the sediments, which is washed with appropriate water and crystallized by ethanol after dried to get another part of ilxin. Two parts of ilxin are put together and recrystallized for several times to get the pure ilxin, which content can be more than 98.0%.

The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter protein, such as SGLTl, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.

The object of the invention is a multiple-channel test devise based on immunodiffusion and immunochromatography, which enables the simultaneous or parallel determination of several analytes. In the test devise, it is possible to group together different combinations of markers recognizing allergens, myocardial infarction markers, venereal disease analytes, blood screening analytes, respiratory infection producing agents, IgG, IgA and IgM antibodies, other infectious disease producing agents as well as various cancer markers. The multiple-channel test devise comprises a porous carrier material on which a channel network has been formed by etching the carrier material by laser to form a shaped figure that contains several channels. In the channels, various specific binding reagents have been immobilized, which enable the diagnoses of a target illness and / or syndrome. The sample application point is optionally provided with a filter and optionally contains a label mobilizable by the analyzable sample and a specific binding reagent. Also the method for the production of the test device and its use are disclosed in the invention.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

The invention relates to a non-invasive attached telemetering electrocardiographic recording method having an ultra-long record period and an ultra-high storage capacity. By using the method, characteristic values of electrocardiographic waves can be safely, stably and clearly acquired under the natural physiological state of a human body within a long period (more than 15 days), microvolt-level measurements of T-wave alternans can be acquired, and the collection, processing and high-capacity storage of electrocardiographic waves can be completed; and multiple electrocardiographic recording pasters can be used to realize the simultaneous recording of multi-channel body surface electrocardiograms, and a computer data processing and analysis system can complete the data monitoring and analysis, image display, data storage and printing and output of the recorded signals and realize the networking transmission of the electrocardiosignals. The clinical indications of the device include: symptoms related to suspected arrhythmia; determination of arrhythmia property, and completion of reasonably evaluating anti-arrhythmia treatment and monitoring myocardial ischemia; evaluation of anemic heart disease treatment measures; instructions to acute myocardial infarction patients before leaving hospital and during convalescence; and installation, detection and function assessment of sudden cardiac death and heart pacemakers.

An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.

The invention discloses a N, N'-difluoro-substituted-phenyl derivative of 4-methoxyl-1, 3-phenyldiamide, and relative application, while the compound can restrain platelet aggregation activity, to treat the diseases as cardiac infarction, cerebrovascular disorder, pulmonary embolism and atherosclerosis, with antipyretic, analgesia, and antiphlogistic activities.

A medical-use image data analyzing apparatus, aiming for detecting with a simple operation, presence or extent of difference in timing of movements among local portions as to facilitate diagnosis of diseases such as cardiac infarction, includes: an image input unit configured to input an image data of a test subject; a movement detector configured to detect movement of the test subject, based on the image data; a time distance calculator which calculates a time distance up to a time point when movement parameter, which is calculated from the movement, reaches local maximum or local minimum; a display device configured to display the time distances for the respective local portions of the test subject; and a memory.

The invention relates to an imaging method and a device for visualizing coronary heart disease, in particular cardiac infarction lesions, in which at least one image of the heart or heart region comprising at least the myocardium is recorded and reproduced using computed tomography part. The method is characterized in that, by windowing the measured data of the image or the data derived therefrom in the region of the myocardium, regions with insufficient blood supply and / or damage are segmented and displayed in the image in a distinctive manner. In particular, the method according to the invention and the associated device can be used to graphically display the extent of damage after a heart attack.

The invention discloses an immunochromatographic test strip for detecting cardiac infarction and heart failure and a preparation method thereof, and is intended to provide an immunochromatographic test strip that provides detection results accurately determinable and causes few cross reactions. The immunochromatographic test strip comprises a bottom board; a sample pad, a binding pad, a reaction film and an absorbing pad are linked to the bottom board; CRP (C-reactive protein) antibody and chicken IgY labeled by 300 nm immunofluorescence spheres are sprayed to the binding pad, and NT-proBNP antibody labeled by 200 nm immunofluorescence spheres is also sprayed thereto; the reaction film is parallelly provided with a C quality control line, a T1 detection line and a T2 detection line; the C quality control line is coated with goat anti-chicken IgY; the T1 detection line is coated with antigen CRP protein; the T2 detection line is coated with anti-NT-proBNP antibody.

Methods and apparatuses, including devices and systems, for remote and detection and / or diagnosis of acute myocardial infarction (AMI). In particular, described herein are handheld and adhesive devices having an electrode configuration capable of recording three orthogonal ECG lead signals in an orientation-specific manner, and transmitting these signals to a processor. The processor may be remote or local, and it may automatically or semi-automatically detect AMI, atrial fibrillation or other heart disorders based on the analyses of the deviation of the recorded 3 cardiac signals with respect to previously stored baseline recordings.

The invention discloses a non-invasive cardiac infarction classification model construction method based on a stack type self-encoder and a support vector machine. At a training stage, movement information of a heart is obtained by using a collected cardiac magnetic resonance image; a self-encoder is trained by using an image block based on fusion of image information and movement information as an input and a corresponding infarction situation as a tag; inputted data are preprocessed by using a denoising self-encoder; all variable factors of the upper layer are utilized during the high-dimensional information learning process and thus deep features of the inputted data are learned; and then with a support vector machine, sample classification is carried out by using the learned deep features as the input and a corresponding tag. According to the invention, cardiac infarction classification prediction is realized from the perspective of data driving, so that a problem of time and effort wasting caused by infarction prediction with contrast agent injection clinically is solved.

The invention discloses function and application of a Caspase activation and recruitment domain 3 (Card3) gene in a coronary atherosclerotic heart disease. The Card3 gene knockout mice and heart specific Card3 transgenic mice are taken as objects, and a research is carried out on a myocardial infarction model caused by blocking mice heart ramus descendens anterior arteriae coronariae sinistrae. The result proves that compared with WT mice, the cardiac infarction proportion, and the degrees of myocardial hypertrophy and fibrosis of the Card3 gene knockout mice are obviously inhibited, and the cardiac function is obviously improved; the phenotype of the Card3 transgenic mice is contrary to that of the Card3 gene knockout mice. Consequently, the Card3 gene can promote and increase development and progression of the coronary atherosclerotic heart disease, the Card3 can be used as a drug target for screening the drugs for treating the coronary atherosclerotic heart disease, and the inhibitor of the Card3 can be applied to preparation of a drug for treating the coronary atherosclerotic heart disease.

The invention discloses an application of signal regulatory protein alpha (SIPR alpha, SHPS-1) genes in coronary atherosclerotic heart diseases, belonging to the field of function and application of genes. Mice of which the SHPS-1 genes are knocked out and cardiac-specific SHPS-1 transgenic mice are adopted as experimental subjects; MI (myocardial infarction) models are formed by blocking LAD (left anterior descending coronary artery) of the hearts of the mice, and the result shows that compared with WT (wild type) control mice, the cardiac infarction proportion, cardiac hypertrophy and degree of fibrosis of the mice of which the SHPS-1 genes are knocked out, subjected to an MI operation, are obviously inhibited, and the cardiac functions of the mice are obviously improved; the cardiac infarction proportion, cardiac hypertrophy and degree of fibrosis of the cardiac-specific SHPS-1 transgenic mice are obviously increased, and the cardiac functions of the mice are obviously worsened, so that the result shows that the SHPS-1 genes can promote and worsen the occurrence and development of the coronary atherosclerotic heart diseases; SHPS-1 can be used as a medicament target for screening medicaments which are used for treating the coronary atherosclerotic heart diseases; an inhibitor of SHPS-1 can be used for preparing the medicaments for treating the coronary atherosclerotic heart diseases.

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and / or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

An effervescent tablet containing coenzyme Q10 and anthocyanidin and a preparing method thereof are provided and relate to the technical field of healthcare products. The effervescent tablet is mainly prepared from, by mass, 200-300 parts of the coenzyme Q10, 600-800 parts of the anthocyanidin, 400-600 parts of a stabilizer, 1000-1200 parts of an acid agent, and 800-1000 parts of an alkali agent. The effervescent tablet relieves the technical problem that medicines in the market at present are mostly western medicines which have large intrinsic adverse effects and accompanying side effects and influence body health of eaters. The effervescent tablet achieves technical effects of capability of effectively activating cell activity, reducing blood lipids, stabilizing blood glucose and preventing cardiac infarction, convenient taking, rapid production of desired effects, high bioavailability, capability of boosting body immunity and maintaining body health, and no side or toxic effects.

Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I)or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic actionwherein each symbol is as defined in the specification.The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic actionwherein each symbol is as defined in the specification.The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

The invention discloses a function and an application of a DKK3 gene in coronary atherosclerotic heart disease. The DKK3 gene knocked-out mice and cardiac specific DKK3 transgenic mice are used as the experimental subjects; and the research is carried out with the mice model suffering from myocardial infarction caused by blocking ramus descendens anterior arteriae coronariae sinistrae. The result shows that the cardiac infarction proportion, myocardial hypertrophy and the degree of fibrosis of the DKK3 gene knocked-out mice are obviously increased, and cardiac function is obviously pejorative by being compared with DDK3+ / + control mice; and in addition, the cardiac infarction proportion, myocardial hypertrophy and the degree of fibrosis of the cardiac specific DKK3 transgenic mice are obviously inhibited, and the cardiac function is obviously improved. Therefore, the function of DKK3 gene coronary atherosclerotic heart disease is mainly expressed by protecting coronary atherosclerotic heart disease. DKK3 with the function above can be used for preparing a medicine for treating coronary atherosclerotic heart disease.

Methods and apparatuses, including devices and systems, for remote and detection and / or diagnosis of acute myocardial infarction (AMI). In particular, described herein are handheld and adhesive devices having an electrode configuration capable of recording three orthogonal ECG lead signals in an orientation-specific manner, and transmitting these signals to a processor. The processor may be remote or local, and it may automatically or semi-automatically detect AMI, atrial fibrillation or other heart disorders based on the analyses of the deviation of the recorded 3 cardiac signals with respect to previously stored baseline recordings.

The preparation method of injection preparation containing above 70% of arginine lipase active component with the functions of dissolving thrombosis, anticoagulant, resisting platelet agglutination and improving microcirculation for curing thrombosis, encephalatrophy, coronary heart disease, cardiac infarction, thromboangiitis obliterans, thrombotic phlebitis, Raynaud's disease, aorto-arteritis and hyperviscosity disease, etc. includes the following steps: using G75 chromatographic column to make chromatographic separation, taking Agkistrodon halys venin and dissolving it in phosphate buffer liquor, centrifugal sample-charging, column-charing, eluting with phosphate buffer liquor, collecting enzyme active peak, concentrating and freeze-drying, and using Sephadex-A25 chromatographic columnto make chromatographic separation, dissolving the chromatographic sample in Tris-HCl buffer liquor, soaking in gel with PH7.0, charging column, eluting with NaCl buffer liquor, collecting enzyme active peak, concentrating and freeze-drying to obtain dried powder.

An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.

The present invention relates to prodrug derivatives of dabigatran, their use in the treatment and / or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and / or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.

The invention relates to the field of cherry processing and discloses cosmetic cherry dry red wine which is prepared from, by weight, 200-300 parts of cherry, 25-30 parts of aloe, 15-20 parts of longan, 10-15 parts of raspberry, 5-10 parts of motherwort honey and 0.2-0.3 part of wine yeast. Antioxidation effect of cherry seeds, which is neglected by people, is utilized fully, and the cherry seeds are added into fermentation liquid, so that the cherry dry red wine obtained through two times of fermentation is strong in fruit aroma, remarkable in refreshing and skin-beautifying efficacy and unique in medical value and has effects of treating anemia, softening blood vessels, improving circulation, preventing diseases and beautifying face if being drunk for a long time properly; the dry red wine is high in selenium content, selenium is a strong oxidant, and selenium together with vitamin E can prevent and treat angina and myocardial infarction and prevent blood pressure increase and thrombosis.

The invention discloses an N, N'-difluoro-substituted-phenyl derivative of 4-methoxyl-1, 3-phenyldiamide, and relative applications. The compound has activity of suppressing platelet aggregation, and can be used for treating the diseases such as cardiac infarction, cerebrovascular disorder, pulmonary embolism and atherosclerosis, with antipyretic, analgesia and antiphlogistic activities.